The world manages diabetes.
We end it.

DiaCell Therapeutics is a company pioneering a personalized cure for diabetes by activating a patient’s own cells to produce insulin that, when transplanted back, then reduces the need for lifelong immunosuppression and its associated risks. Because for 589 million people, “managing” diabetes using insulin is no longer good enough.

More Than a Biotech Company

DiaCell is a mission to deliver a permanent solution to diabetes. With strong institutional backing and a clear path forward, we're inviting strategic investors and partners to join us in making the end of diabetes a reality.

For 589 million people living with diabetes, "manageable" is no longer good enough.

589

million
people living with diabetes

True Cure Potential

Our autologous approach uses a patient’s own cells—significantly reducing, and hopefully eliminating, the need for lifelong immunosuppression and the risks that come with it.

Proven Leadership

Led by Dr. James Shapiro, inventor of the world-renowned Edmonton Protocol, with 42 years of breakthrough diabetes research.

Beyond Theory

We’ve achieved proof of concept—successfully reversing diabetes in mice using human cells. First-in-human trials: 18–24 months.

Backed by:

42

years
of transplant research data

Diabetes Is Relentless

While diabetes is manageable, life with it is unrelenting. Alarms at 3 a.m. Meals turned into dosing math. Exhaustion, nausea, dizziness when glucose runs too high or too low. The quiet fear of a device failing. The grind of clinic visits.

And then there’s the invisible war. As one of the world’s deadliest diseases, diabetes accelerates heart disease, kidney failure, liver disease, blindness, amputations, dementia, and stroke—stealing decades from otherwise promising lives.

We exist to improve the lives of people living with diabetes and reduce the burden on our healthcare system and to end diabetes.

5.8

million
people in Canada are impacted

$

18

billion
per year in direct healthcare costs across Canada

$

1.3

trillion
USD in 2015 globally and is projected to climb to $2.5 trillion by 2030

DiaCell
In The News

Edmonton Journal article from Sep 4, 2025

National Geographic article from Nov 17, 2025